Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVO 390

X
Drug Profile

EVO 390

Alternative Names: EVO-390; ROR gamma t modulator - Evommune; RORγt modulator - Evommune

Latest Information Update: 23 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dermira
  • Developer Evommune
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Preclinical Psoriasis

Most Recent Events

  • 15 Sep 2021 ROR gamma t modulator - Evommune is available for licensing as of 15 Sep 2021. https://www.evommune.com/ (Evommune website, September 2021)
  • 09 Sep 2021 Preclinical trials in Psoriasis in USA (unspecified route) before September 2021 (Evommune pipeline, September 2021)
  • 09 Sep 2021 Evommune plans clinical trials for EVO 390 in Psoriasis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top